IP Library › Granted Patent US 10,695,448
Granted Patent B2
US 10,695,448 · App. 16/443,183 · Granted Jun 30, 2020

Process for the preparation of hyperpolarized carboxylate compounds

Inventors: Silvio Aime (Carignano, IT); Tommaso Boi (Borgo San Dalmazzo, IT); Erika Cerutti (Bra, IT); Francesca Reineri (Cuneo, IT)
Assignee: BRACCO IMAGING S.P.A.
A61K51/0402A61B5/055A61K49/10B01J31/2404C07C51/09C07C51/412C07C67/283C07C69/14C07C69/155C07C69/68C07C69/716C07C227/20C07C231/12C07C233/47G01R33/5601A61K49/06B01J2531/822C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,695,448
App. No.
16/443,183
Granted
Jun 30, 2020
Kind
B2
Abstract

The present invention relates to a process for the preparation of aqueous solutions of [1- 13 C]-hyperpolarized carboxylate containing molecules of diagnostic interest that comprises parahydrogenating with molecular parahydrogen unsaturated alkenyl or alkynyl esters of the concerned 13 C-carboxylate molecules.

Claims (41)

1. A para-hydrogenated ester of formula (III)

R—C*(O)—O—R″  (III)

in which:

C* denotes a naturally 13 C enriched or, optionally, 13 C labeled carboxylate carbon atom;

R is a C 1 -C 5 linear or branched alkyl chain which is optionally interrupted by, or substituted with, one or more groups selected from the group consisting of carbonyl (—CO—), hydroxyl (—OH), amino (—NHR 1 ), halogen atom, halo-alkyl group, carbocyclic aliphatic moiety optionally substituted by one or more hydroxyl groups, and aromatic moiety optionally substituted by one or more hydroxyl groups:

R 1 is H or an amino protecting group; and

R″ is a parahydrogenated allyl residue,

or a physiologically acceptable salt thereof.

2. A method for diagnostic MR imaging of a body organ, region, fluid or tissue, or for MR assessment of a biological parameter or metabolic profile of diagnostic interest in an individual patient that comprises:

i) obtaining an unsaturated alkenyl or alkynyl ester of a carboxylate containing molecule of formula (II)

R—C*(O)—O—R′  (II)

in which:

C* denotes the naturally 13 C enriched or, optionally, 13 C labeled carboxylate carbon atom undergoing 13 C hyperpolarization;

R′ is an allyl of formula —CH 2 —CH═CH 2 or a propargyl residue of formula —CH 2 —C≡CH;

R is a C 1 -C 5 linear or branched alkyl chain, which is optionally interrupted by, or substituted with, one or more groups selected from the group consisting of carbonyl (—CO—), hydroxyl (—OH), amino (—NHR 1 ), halogen atom, halo-alkyl group, carbocyclic aliphatic moiety optionally substituted by one or more hydroxyl groups, and aromatic moiety optionally substituted by one or more hydroxyl groups; and

R 1 is H or an amino protecting group,

or a physiologically acceptable salt thereof, and

reacting said unsaturated ester with a molecular para-hydrogen in an aqueous solvent, optionally including an amount from 10% to 30% of an organic solvent selected from short-chain alcohol or acetone, and in the presence of a water soluble hydrogenation catalyst, to produce a para-hydrogenated ester with an [1- 13 C]-carboxylate carbon atom and added polarized hydrogen;

ii) inducing a polarization transfer from the added polarized hydrogen to the [1- 13 C]-carboxylate carbon atom of the para-hydrogenated ester to produce an [1- 13 C]-hyperpolarized ester; and

iii) hydrolyzing the [1- 13 C]-hyperpolarized ester by adding to the aqueous solution of the [1- 13 C]-hyperpolarized ester obtained at step ii) a base promoting its hydrolysis, to give the aqueous solution of the [1- 13 C]-hyperpolarized carboxylate containing molecule of interest, and collecting an aqueous solution of the [1- 13 C]-hyperpolarized carboxylate containing molecule, or of the corresponding [1- 13 C]-hyperpolarized carboxylic acid;

(iv) removing the hydrogenation catalyst and the optional organic solvent from the obtained aqueous solution, to give the aqueous solution of the [1- 13 C]-hyperpolarized carboxylate containing molecule of interest ready for use in an in vivo application;

v) administering the aqueous solution to the individual patient, or contacting the aqueous solution with an ex vivo sample of the body organ, region, fluid or tissue of the individual patient;

vi) exposing the administered individual patient, or the contacted ex vivo sample to a radiation frequency allowing to excite the hyperpolarized [1- 13 C]-carboxylate carbon atom of the [1- 13 C]-hyperpolarized carboxylate containing molecule;

vii) recording a signal intensity generated by the excited [1- 13 C]-carboxylate carbon atom of the [1- 13 C]-hyperpolarized carboxylate containing molecule and/or of a metabolite or catabolite thereof; and

viii) obtaining an image of the individual patient body organ, region, or tissue, or a suitable estimate of the biological parameter or metabolic profile of interest from the signal intensity.

3. A method for diagnostic MR imaging of a body organ, region, fluid, or tissue, or for MR assessment of a biological parameter or metabolic profile of diagnostic interest in an individual patient comprising:

i) obtaining an unsaturated alkenyl or alkynyl ester of a carboxylate containing molecule of formula (II)

R—C*(O)—O—R′  (II)

in which:

C* denotes the naturally 13 C enriched or, optionally, 13 C labeled carboxylate carbon atom undergoing 13 C hyperpolarization;

R′ is an allyl of formula —CH 2 —CH═CH 2 or a propargyl residue of formula —CH 2 —C≡CH;

R is a C 1 -C 5 linear or branched alkyl chain, which is optionally interrupted by, or substituted with, one or more groups selected from the group consisting of carbonyl (—CO—), hydroxyl (—OH), amino (—NHR 1 ), halogen atom, halo-alkyl group, carbocyclic aliphatic moiety optionally substituted by one or more hydroxyl groups, and aromatic moiety optionally substituted by one or more hydroxyl groups; and

R 1 is H or an amino protecting group,

or a physiologically acceptable salt thereof, and reacting the unsaturated ester with a molecular para-hydrogen in an organic solvent, or a suitable mixture of organic solvents, and in the presence of a hydrogenation catalyst soluble in the organic solvent and insoluble in an aqueous solvent;

ii) inducing a polarization transfer from the added polarized hydrogen to the [1- 13 C]-carboxylate carbon atom of the para-hydrogenated ester to produce an [1- 13 C]-hyperpolarized ester;

iii) diluting the organic solution of the [1- 13 C]-hyperpolarized ester obtained at step ii) with an aqueous solution promoting the hydrolysis of the ester to the corresponding water soluble [1- 13 C]-hyperpolarized carboxylate containing molecule, or the corresponding carboxylic acid, and then collecting, by phase transfer extraction, the aqueous solution of the [1- 13 C]-hyperpolarized compound of interest, which is ready for use in an in vivo application;

iv) administering the collected aqueous solution to the individual patient, or contacting the aqueous solution with an ex vivo sample of the body organ, fluid, or tissue of the individual patient;

v) exposing the administered individual patient, or the contacted ex vivo sample to a radiation frequency allowing to excite the hyperpolarized [1- 13 C]-carboxylate carbon atom of the [1- 13 C]-hyperpolarized carboxylate containing molecule;

vi) recording a signal intensity generated by the excited hyperpolarized [1- 13 C]-carboxylate carbon atom of the [1- 13 C]-hyperpolarized carboxylate containing molecule and/or of any suitable metabolite or catabolite thereof; and

vii) obtaining an image of the individual patient body, organ, region, or tissue, or a suitable estimate of the biological parameter or metabolic profile of interest from the signal intensity.

4. The ester according to claim 1 , wherein R is a hydroxyethyl residue of formula CH 3 CH(OH)—.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2019
From: AIME, SILVIO; BOI, TOMMASO; CERUTTI, ERIKA; REINERI, FRANCESCA
To: BRACCO IMAGING S.P.A.
Reel/Frame 049495/0468 →
Priority Claims (1)
EP 13190409 · Oct 28, 2013 · regional
Continuity (2)
Division 15031860
Related Publication 20190298863A1 · Oct 3, 2019